Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults.
Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults.
复制标题
DOI：
10.1016/j.cmi.2021.08.001
复制
发表时间：
2021-12
期刊：
影响因子：
--
通讯作者：
Navarro D
中科院分区：
文献类型：
--
作者：
Costa R;Bueno F;Albert E;Torres I;Carbonell-Sahuquillo S;Barrés-Fernández A;Sánchez D;Padrón C;Colomina J;Lázaro Carreño MI;Bretón-Martínez JR;Martínez-Costa C;Navarro D
比较患有2019冠状病毒病（COVID-19）或无症状的儿童和成人上呼吸道（URT）中严重急性呼吸综合征冠状病毒2 (SARS-CoV-2) RNA载量的研究得出了不一致的结果。在这里，我们进行了一项回顾性的单中心研究来解决这个问题。纳入1184名连续受试者（256名儿童和928名成人），鼻咽渗出液中SARS-CoV-2 RNA检测呈阳性；其中，新冠肺炎确诊病例424例（儿童121例、成人303例），无症状密切接触者760例（儿童135例、成人625例）。使用TaqPath COVID-19 Combo Kit （Thermo Fisher Scientific， MS， USA）进行SARS-CoV-2 RNA检测。AMPLIRUN®TOTAL SARS-CoV-2 RNA Control （Vircell SA, Granada, Spain）用于估计SARS-CoV-2 RNA载量（以拷贝数/mL为单位）。使用实验室诊断时（单个标本/患者）的SARS-CoV-2 RNA载量进行比较。儿童初始SARS-CoV-2 RNA载量中位数（6.98 log10拷贝/mL，范围3.0-11.7）低于成人（7.14 log10拷贝/mL，范围2.2-13.4）。对于无症状个体，儿童（6.20 log10拷贝/mL，范围1.8-11.6）和成人（6.48 log10拷贝/mL，范围1.9-11.8）的中位SARS-CoV-2 RNA载量相当（p 0.97）。有COVID-19症状的儿童表现出的SARS-CoV-2 RNA载量（6.98 log10拷贝/mL，范围3.0-11.7）与无症状的儿童（6.20 log10拷贝/mL，范围1.8-11.6）相当（p 0.61）。与此同时，在成人中，有症状者的中位SARS-CoV-2 RNA载量（7.14 log10拷贝/mL，范围2.2-13.4）显著高于无症状者（6.48 log10拷贝/mL，范围1.9-11.8）（p < 0.001）。总体而言，观察到的儿童上呼吸道SARS-CoV-2 RNA清除率比成人快。根据诊断时的病毒载量数据，我们的研究结果表明，感染sars - cov -2的儿童，无论是否患有COVID-19，可能表现出与成人相当的NP病毒载量。然而，儿童的病毒脱落时间可能比成人短。
Studies comparing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA load in the upper respiratory tract (URT) between children and adults—who either presented with coronavirus disease 2019 (COVID-19) or were asymptomatic—have yielded inconsistent results. Here, we conducted a retrospective, single-centre study to address this issue. Included were 1184 consecutive subjects (256 children and 928 adults) testing positive for SARS-CoV-2 RNA in nasopharyngeal exudates (NPs); of these, 424 (121 children and 303 adults) had COVID-19 and 760 (135 children and 625 adults) were asymptomatic close contacts of COVID-19 patients. SARS-CoV-2 RNA testing was carried out using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, MS, USA). The AMPLIRUN® TOTAL SARS-CoV-2 RNA Control (Vircell SA, Granada, Spain) was used for estimating SARS-CoV-2 RNA loads (in copies/mL). SARS-CoV-2 RNA loads at the time of laboratory diagnosis (single specimen/patient) were used for comparison purposes. Median initial SARS-CoV-2 RNA load was lower (p 0.094) in children (6.98 log10 copies/mL, range 3.0–11.7) than in adults (7.14 log10 copies/mL, range 2.2–13.4) with COVID-19. As for asymptomatic individuals, median SARS-CoV-2 RNA load was comparable (p 0.97) in children (6.20 log10 copies/mL, range 1.8–11.6) and adults (6.48 log10 copies/mL, range 1.9–11.8). Children with COVID-19 symptoms displayed SARS-CoV-2 RNA loads (6.98 log10 copies/mL, range 3.0–11.7) comparable to those of their asymptomatic counterparts (6.20 log10 copies/mL, range 1.8–11.6) (p 0.61). Meanwhile in adults, median SARS-CoV-2 RNA load was significantly higher in symptomatic (7.14 log10 copies/mL, range 2.2–13.4) than in asymptomatic subjects (6.48 log10 copies/mL, range 1.9–11.8) (p < 0.001). Overall, the observed URT SARS-CoV-2 RNA clearance rate was faster in children than in adults. Based on viral load data at the time of diagnosis, our results suggest that SARS-CoV-2-infected children, with or without COVID-19, may display NP viral loads of comparable magnitude to those found in their adult counterparts. However, children may have shorter viral shedding than adults.
登录
查看更多内容
DOI：
10.1016/j.cmi.2021.01.011
发表时间：
2021-04
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Qiu X;Nergiz AI;Maraolo AE;Bogoch II;Low N;Cevik M
通讯作者：
Cevik M
影响因子：
11.8
作者：
Bullard, Jared;Dust, Kerry;Poliquin, Guillaume
通讯作者：
Poliquin, Guillaume
DOI：
10.1016/s1473-3099(20)30985-3
发表时间：
2021-05
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Marks M;Millat-Martinez P;Ouchi D;Roberts CH;Alemany A;Corbacho-Monné M;Ubals M;Tobias A;Tebé C;Ballana E;Bassat Q;Baro B;Vall-Mayans M;G-Beiras C;Prat N;Ara J;Clotet B;Mitjà O
通讯作者：
Mitjà O
DOI：
10.1093/cid/ciaa1693
发表时间：
2021-11-02
期刊：
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子：
--
作者：
Hurst JH;Heston SM;Chambers HN;Cunningham HM;Price MJ;Suarez L;Crew CG;Bose S;Aquino JN;Carr ST;Griffin SM;Smith SH;Jenkins K;Pfeiffer TS;Rodriguez J;DeMarco CT;De Naeyer NA;Gurley TC;Louzao R;Zhao C;Cunningham CK;Steinbach WJ;Denny TN;Lugo DJ;Moody MA;Permar SR;Rotta AT;Turner NA;Walter EB;Woods CW;Kelly MS
通讯作者：
Kelly MS
影响因子：
39
作者：
Lee, Seungjae;Kim, Tark;Kim, Tae Hyong
通讯作者：
Kim, Tae Hyong